aktiencheck.de - Forum - GENAERA CORP

Löschung

Genaera läuft seit Tagen super !, Ich denke, da ist noch mehr drin. Der Titel ist grundlos nach unten geprügelt worden. Waren schon immer und jetzt erst recht Übernahmekandidat für einen Pharmariesen. [mehr]

Genaera 300% Kandidat

Genaera Corporation Presents Encouraging Data, Genaera Corporation Presents Encouraging Data on Bilateral Visual Acuity in Subjects From EVIZON Phase II Trials PLYMOUTH MEETING, Pa., March 29 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today presented a new subset analysis of EVIZON(TM) (squalamine lactate) clinical data at the IBC Third Annual Ocular Anti- angiogenesis Conference in Cambridge, MA, that suggests the treatment may benefit patients with wet age-related macular degeneration (AMD) whose vision has already significantly deteriorated. In an overview of Phase II clinical trial data, including recently announced 24-week interim results from Study 209 (MSI-1256F-209), Michael J. Gast, M.D., Ph.D., Senior Vice President, Clinical Research and Development, described outcomes for subjects in these studies with fellow affected eyes (i.e., documented disease in the second eye) and poor vision at study entry. "These data, which are consistent across our Phase [mehr]

Tradingidee für Do. 29.4.

wo steht gpc heute eigentlich *gg*, mir egal: hab bei 13,95 EUR verkauft. [mehr]

Biotech TopKaufempfehlung

positive testergebnisse, Genaera Reports Cancer Treatment Results 06.07.2004, 14:22 PM Biopharmaceutical company Genaera Corp.'s cancer treatment squalamine, when combined with chemotherapy, stabilized or reduced tumor sizes in 72 percent of lung cancer patients, the company said Monday. Results from the Phase IIB trial showed that squalamine, when used with carboplatin and paclitaxel, reduced tumor sizes by half or more in 24 percent of patients, the company said. Squalamine is a class of drugs known as anti-angiogenics, which cut off the blood supply to tumor cells. "These interim clinical results of a 72 percent overall response rate, including one durable complete response, with squalamine combination therapy in lung cancer, provide continued evidence of its tremendous potential as an anti- angiogenic therapy," said Genaera president and chief executive Roy C. Levitt. [mehr]